Need help understanding this study?
Leave your email and we’ll get in touch to discuss your questions and possible next steps.
RecruitingNCT07399626
Adaptation and Validation of the Hypomanic Personality Scale (HPS-6) to Romanian
Study assessmentsAges 18–50RomaniaBipolarity
Understand this study
Who could participate?
Listed age limits: 18 years to 50 years.
- Listed locations
- Cluj-Napoca, RomaniaSee all locations and recruitment
- Activities
- Study assessments
- Compensation
- Payment and expense reimbursement have not been verified.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: September 22, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 50
- Sponsor
- Babes-Bolyai University
- Sponsor type
- University
- Study type
- Diagnostic Test
- Intervention type
- DIAGNOSTIC_TEST
- Study phase
- Phase 1, Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- Romania
- Age range
- From 18 Years to 50 Years
- Official registry ID
- NCT07399626
- Official title
Show the full official title
Adaptation and Validation of the Hypomanic Personality Scale (HPS-6) to Romanian.
Recruitment & locations
RecruitingCluj-Napoca
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Babes-Bolyai University, a university.
Who can participate?
Listed age limits: 18 years to 50 years.
Is this study still recruiting?
The registry lists this study as recruiting.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
RecruitingNCT06929273
Long-term safety of KarXT in bipolarity type I
This extension study evaluates the long-term safety and tolerability of KarXT for mania or mania with mixed features in people living with bipolarity type I.
RecruitingNCT07140913
KarXT for manic episodes in bipolarity type I
Researchers compare KarXT with placebo, each added to lithium, valproate or lamotrigine, in people with bipolarity type I experiencing mania, with or without mixed features. They want to know whether adding KarXT improves manic symptoms and assess its safety.
RecruitingNCT06951711
KarXT for manic episodes in bipolarity type I
Researchers compare KarXT with placebo during a three-week hospital treatment period for people with bipolarity type I experiencing mania, with or without mixed features. They assess changes in manic symptoms and monitor safety.